镁在慢性肾脏病中的新角色:过少与过多同样糟糕
Magnesium as a new player in CKD: too little is as bad as too much?
PubMed 文献 · Kidney Int · 2017-01-01
血管钙化是慢性肾脏病的严重并发症,现有治疗策略不足以阻止其进展。Diaz-Tocados等人在尿毒症大鼠模型中证实,补镁可独立于磷结合能力预防血管钙化进展,但需警惕镁过多对骨代谢的不良影响。
要点
- 补镁可独立于磷结合能力预防尿毒症大鼠血管钙化进展
- 镁过多可能对骨代谢产生不良影响
- 镁是有效的钙化抑制剂,是有前景的治疗候选
核心结论
- 补镁可独立于磷结合能力预防尿毒症大鼠模型的血管钙化进展
- 镁过多可能对骨代谢产生不良影响
研究设计与样本
- 尿毒症大鼠模型研究
主要发现
- Diaz-Tocados等人在尿毒症大鼠模型中证实补镁可预防血管钙化进展
- 补镁预防血管钙化的作用独立于磷结合能力
临床怎么用
- 镁是有效的钙化抑制剂,可作为慢性肾脏病血管钙化的治疗候选
- 补镁时需警惕镁过多对骨代谢的不良影响
局限性
- 证据来自尿毒症大鼠模型,尚未在人体中验证
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vascular calcification is a serious complication of chronic kidney disease, but the current therapeutic strategy is insufficient for preventing its progression. Magnesium is a potent inhibitor of calcification and represents a promising therapeutic candidate. Diaz-Tocados and colleagues now demonstrate that magnesium supplementation prevents the progression of vascular calcification in a uremic rat model, independently of the phosphate-binding capacity. We should keep in mind, however, that too much magnesium could have adverse effects on bone metabolism.
来源:Kidney Int,查看原文。版权归原作者所有。
引用
- Hamano N, Komaba H, Fukagawa M, et al. Magnesium as a new player in CKD: too little is as bad as too much? Kidney Int. 2017. PMID: 29055421. doi:10.1016/j.kint.2017.05.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。